Animal models are critical to improve our understanding of the neuronal mechanisms underlying nicotine withdrawal. Nicotine dependence in rodents can be established by repeated nicotine injections, chronic nicotine infusion via osmotic minipumps, oral nicotine intake, tobacco smoke exposure, nicotine vapor exposure, and e-cigarette aerosol exposure. The time course of nicotine withdrawal symptoms associated with these methods has not been reviewed in the literature.
Aim:
The goal of this review is to discuss nicotine withdrawal symptoms associated with the cessation of nicotine, tobacco smoke, nicotine vapor, and e-cigarette aerosol exposure in rats and mice. Furthermore, age and sex differences in nicotine withdrawal symptoms are reviewed.
Results:
Cessation of nicotine, tobacco smoke, nicotine vapor, and e-cigarette aerosol exposure leads to nicotine withdrawal symptoms such as somatic withdrawal signs, changes in locomotor activity, anxiety- and depressive-like behavior, learning and memory deficits, attention deficits, hyperalgesia, and dysphoria. These withdrawal symptoms are most pronounced within the first week after cessation of nicotine exposure. Anxiety- and depressive-like behavior, and deficits in learning and memory may persist for several months. Adolescent (4–6 weeks old) rats and mice display fewer nicotine withdrawal symptoms than adults (>8 weeks old). In adult rats and mice, females show fewer nicotine withdrawal symptoms than males. The smoking cessation drugs bupropion and varenicline reduce nicotine withdrawal symptoms in rodents.
Conclusion:
The nicotine withdrawal symptoms that are observed in rodents are similar to those observed in humans. Tobacco smoke and e-cigarette aerosol contain chemicals and added flavors that enhance the reinforcing properties of nicotine. Therefore, more valid animal models of tobacco and e-cigarette use need to be developed by using tobacco smoke and e-cigarette aerosol exposure methods to induce dependence.
AboboCVMaJLiangD (2012) Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation. Nicotine Tob Res14: 801–808.
2.
AkimotoHOshimaSMichiyamaY, et al. (2018) Metabolic profiling of the hippocampus of rats experiencing nicotine-withdrawal symptoms. Biol Pharm Bull41: 1879–1884.
3.
AlajajiMBowersMSKnackstedtL, et al. (2013) Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice. Psychopharmacology (Berl)228: 419–426.
4.
AlijevicOMcHughDRufenerL, et al. (2020) An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human α4β2 and α7 nicotinic acetylcholine receptors. Phytochemistry170: 112187.
5.
AlkhlaifYBagdasDJacksonA, et al. (2017) Assessment of nicotine withdrawal-induced changes in sucrose preference in mice. Pharmacol Biochem Behav161: 47–52.
6.
Audrain-McGovernJBenowitzNL (2011) Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther90: 164–168.
7.
BagdasDAlkhlaifYJacksonA, et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology138: 72–79.
8.
BagdasDDiesterCMRileyJ, et al. (2019) Assessing nicotine dependence using an oral nicotine free-choice paradigm in mice. Neuropharmacology157: 107669.
9.
BagosiZPalotaiMSimonB, et al. (2016) Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice. Brain Res1652: 21–29.
10.
Barrington-TrimisJLUrmanRBerhaneK, et al. (2016) E-cigarettes and future cigarette use. Pediatrics138: e20160379.
11.
BelluzziJDWangRLeslieFM (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology30: 705–712.
12.
BenowitzNL (2008) Neurobiology of nicotine addiction: Implications for smoking cessation treatment. Am J Med121(Suppl. 1): S3–S10.
13.
BenowitzNL (2009) Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol49: 57–71.
14.
BenowitzNL (2010) Nicotine addiction. N Engl J Med362: 2295–2303.
BenowitzNLKuytFJacobPIII, et al. (1983) Cotinine disposition and effects. Clin Pharmacol Ther34: 604–611.
17.
BenwellMEBalfourDJ (1992) The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol105: 849–856.
18.
BenwellMEBalfourDJAndersonJM (1988) Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem50: 1243–1247.
19.
BialaGWeglinskaB (2005) Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol Res51: 483–488.
20.
BialaGPolakPMichalakA, et al. (2014) Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice. Pharmacol Rep66: 212–222.
21.
BiswasLHarrisonEGongY, et al. (2016) Enhancing effect of menthol on nicotine self-administration in rats. Psychopharmacology (Berl)233: 3417–3427.
22.
BohadanaANilssonFRasmussenT, et al. (2003) Gender differences in quit rates following smoking cessation with combination nicotine therapy: Influence of baseline smoking behavior. Nicotine Tob Res5: 111–116.
23.
BruijnzeelAW (2017) Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl)234: 1419–1437.
24.
BruijnzeelAWBishnoiMvan TuijlIA, et al. (2010) Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl)212: 485–499.
25.
BruijnzeelAWZislisGWilsonC, et al. (2006) Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology32: 955–963.
26.
BrunzellDHStaffordAMDixonCI (2015) Nicotinic receptor contributions to smoking: Insights from human studies and animal models. Curr Addict Rep2: 33–46.
27.
CaoJBelluzziJDLoughlinSE, et al. (2007) Acetaldehyde, a major constituent of tobacco smoke, enhances behavioral, endocrine, and neuronal responses to nicotine in adolescent and adult rats. Neuropsychopharmacology32: 2025–2035.
28.
CasellaGCaponnettoPPolosaR (2010) Therapeutic advances in the treatment of nicotine addiction: Present and future. Ther Adv Chronic Dis1: 95–106.
29.
ChellianRPandyV (2018) Protective effect of alpha-asarone against nicotine-induced seizures in mice, but not by its interaction with nicotinic acetylcholine receptors. Biomed Pharmacother108: 1591–1595.
30.
ChellianRBehnood-RodAWilsonR, et al. (2020) Exposure to smoke from high- but not low-nicotine cigarettes leads to signs of dependence in male rats and potentiates the effects of nicotine in female rats. Pharmacol Biochem Behav196: 172998.
31.
ChellianRPandyVMohamedZ (2018) Alpha-asarone attenuates depression-like behavior in nicotine-withdrawn mice: Evidence for the modulation of hippocampal pCREB levels during nicotine-withdrawal. Eur J Pharmacol818: 10–16.
32.
ChenHMattaSGSharpBM (2007) Acquisition of nicotine self-administration in adolescent rats given prolonged access to the drug. Neuropsychopharmacology32: 700–709.
33.
CohenAGeorgeO (2013) Animal models of nicotine exposure: Relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Front Psychiatry4: 41.
34.
ColeRDPooleRLGuzmanDM, et al. (2015) Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology (Berl)232: 1207–1217.
35.
CooperSYAkersATHendersonBJ (2021) Flavors enhance nicotine vapor self-administration in male mice. Nicotine Tob Res23: 566–572.
36.
CorreaVLFloresRJCarcobaLM, et al. (2019) Sex differences in cholinergic systems in the interpeduncular nucleus following nicotine exposure and withdrawal. Neuropharmacology158: 107714.
37.
CraigELZhaoBCuiJZ, et al. (2014) Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data. Drug Metab Dispos42: 1447–1455.
38.
CrooksPABardoMTDwoskinLP (2014) Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol69: 513–551.
39.
CryanJFBruijnzeelAWSkjeiKL, et al. (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl)168: 347–358.
40.
DamajMIGrabusSDNavarroHA, et al. (2010) Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. J Pharmacol Exp Ther334: 1087–1095.
41.
DamajMIKaoWMartinBR (2003) Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther307: 526–534.
42.
DandekarMPNakhateKTKokareDM, et al. (2011) Effect of nicotine on feeding and body weight in rats: Involvement of cocaine- and amphetamine-regulated transcript peptide. Behav Brain Res219: 31–38.
43.
DavisJAGouldTJ (2007) Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology32: 2011–2019.
44.
DavisJAJamesJRSiegelSJ, et al. (2005) Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci25: 8708–8713.
45.
de la PeñaJBAhsanHMBotanasCJ, et al. (2016) Cigarette smoke exposure during adolescence but not adulthood induces anxiety-like behavior and locomotor stimulation in rats during withdrawal. Int J Dev Neurosci55: 49–55.
46.
de la PeñaJBAhsanHMBotanasCJ, et al. (2014) Adolescent nicotine or cigarette smoke exposure changes subsequent response to nicotine conditioned place preference and self-administration. Behav Brain Res272: 156–164.
47.
DwoskinLPTengLBuxtonST, et al. (1999) (S)-(−)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther288: 905–911.
48.
ElhassanSBagdasDDamajMI (2017) Effects of nicotine metabolites on nicotine withdrawal behaviors in mice. Nicotine Tob Res19: 763–766.
49.
FowlerJSVolkowNDWangGJ, et al. (1996a) Inhibition of monoamine oxidase B in the brains of smokers. Nature379: 733–736.
50.
FowlerJSVolkowNDWangGJ, et al. (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A93: 14065–14069.
51.
FowlerJSWangGJVolkowND, et al. (2000) Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. Am J Psychiatry157: 1864–1866.
52.
FudalaPJIwamotoET (1986) Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol. Biochem Behav25: 1041–1049.
53.
GäddnäsHPiepponenTPAhteeL (2002) Mecamylamine decreases accumbal dopamine output in mice treated chronically with nicotine. Neurosci Lett330: 219–222.
GoldABLermanC (2012) Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet131: 857–876.
56.
GonzalesDRennardSINidesM, et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA296: 47–55.
57.
GouldTJPortugalGSAndréJM, et al. (2012) The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology62: 2118–2125.
58.
GrabusSDMartinBRBatmanAM, et al. (2005) Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl)178: 183–192.
59.
GrabusSDMartinBRBrownSE, et al. (2006) Nicotine place preference in the mouse: Influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl)184: 456–463.
60.
GriffithsRRHenningfieldJEBigelowGE (1982) Human cigarette smoking: Manipulation of number of puffs per bout, interbout interval and nicotine dose. J Pharmacol Exp Ther220: 256–265.
61.
HallFSDer-AvakianAGouldTJ, et al. (2015) Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev58: 168–185.
62.
HamiltonKRBergerSSPerryME, et al. (2009) Behavioral effects of nicotine withdrawal in adult male and female rats. Pharmacol Biochem Behav92: 51–59.
63.
HamiltonKRPerryMEBergerSS, et al. (2010) Behavioral effects of nicotine withdrawal differ by genetic strain in male and female adolescent rats. Nicotine Tob Res12: 1236–1245.
64.
HamoudaAKJacksonABagdasD, et al. (2018) Reversal of nicotine withdrawal signs through positive allosteric modulation of α4β2 nicotinic acetylcholine receptors in male mice. Nicotine Tob Res20: 903–907.
65.
HarrisACTallyLMuelkenP, et al. (2015) Effects of nicotine and minor tobacco alkaloids on intracranial-self-stimulation in rats. Drug Alcohol Depend153: 330–334.
66.
HerraizTChaparroC (2005) Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun326: 378–386.
67.
HilarioMRTurnerJRBlendyJA (2012) Reward sensitization: Effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology37: 2661–2670.
68.
HughesJR (2007) Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine Tob Res9: 315–327.
69.
HughesJRGustSWSkoogK, et al. (1991) Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry48: 52–59.
70.
HukkanenJJacobPBenowitzNL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev57: 79–115.
71.
HurtRDSachsDPGloverED, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med337: 1195–1202.
72.
IgariMAlexanderJCJiY, et al. (2014) Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology39: 455–465.
73.
IsolaRVogelsbergVWemlingerTA, et al. (1999) Nicotine abstinence in the mouse. Brain Res850: 189–196.
74.
JacksonAPapkeRLDamajMI (2018) Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal. Psychopharmacology (Berl)235: 1897–1905.
75.
JacksonKJJacksonACarrollFI, et al. (2015a) Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology97: 270–274.
76.
JacksonKJKotaDHMartinBR, et al. (2009) The role of various nicotinic receptor subunits and factors influencing nicotine conditioned place aversion. Neuropharmacology56: 970–974.
77.
JacksonKJMartinBRChangeuxJP, et al. (2008) Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther325: 302–312.
78.
JacksonKJMuldoonPPDe BiasiM, et al. (2015b) New mechanisms and perspectives in nicotine withdrawal. Neuropharmacology96: 223–234.
79.
JarvisMJRussellMABenowitzNL, et al. (1988) Elimination of cotinine from body fluids: Implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health78: 696–698.
80.
JohnsonPMHollanderJAKennyPJ (2008) Decreased brain reward function during nicotine withdrawal in C57BL6 mice: Evidence from intracranial self-stimulation (ICSS) studies. Pharmacol Biochem Behav90: 409–415.
81.
JonkmanSHenryBSemenovaS, et al. (2005) Mild anxiogenic effects of nicotine withdrawal in mice. Eur J Pharmacol516: 40–45.
82.
JorenbyDEHaysJTRigottiNA, et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA296: 56–63.
83.
JorenbyDELeischowSJNidesMA, et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med340: 685–691.
84.
KandelDBHuM-CGrieslerPC, et al. (2007) On the development of nicotine dependence in adolescence. Drug Alcohol Depend91: 26–39.
85.
KaraconjiIB (2005) Facts about nicotine toxicity. Arh Hig Rada Toksikol56: 363–371.
86.
KaurGPinkstonRMcLemoreB, et al. (2018) Immunological and toxicological risk assessment of e-cigarettes. Eur Respir Rev27: 170119.
87.
KenneyJWAdoffMDWilkinsonDS, et al. (2011) The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology (Berl)217: 353–365.
88.
KennyPJMarkouA (2001) Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav70: 531–549.
89.
KotaDMartinBRDamajMI (2008) Age-dependent differences in nicotine reward and withdrawal in female mice. Psychopharmacology (Berl)198: 201–210.
90.
KotaDMartinBRRobinsonSE, et al. (2007) Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther322: 399–407.
91.
KotagaleNRChopdeCTUmekarMJ, et al. (2015) Chronic agmatine treatment prevents behavioral manifestations of nicotine withdrawal in mice. Eur J Pharmacol754: 190–198.
92.
LawsonGMHurtRDDaleLC, et al. (1998) Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol38: 502–509.
93.
LefeverTWLeeYOKovachAL, et al. (2017) Delivery of nicotine aerosol to mice via a modified electronic cigarette device. Drug Alcohol Depend172: 80–87.
94.
Le FollBGoldbergSR (2005) Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl)178: 481–492.
95.
LeventhalAMWatersAJBoydS, et al. (2007) Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol15: 21–36.
96.
LiuZLiuXWLuSF, et al. (2014) Effect of nicotine withdrawal on pain sensitivity in rats to mechanical stimulation and thermal stimulation. Eur Rev Med Pharmacol Sci18: 2759–2765.
97.
LockmanPRMcAfeeGGeldenhuysWJ, et al. (2005) Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J Pharmacol Exp Ther314: 636–642.
98.
McRobbieHLeeMJuniperZ (2005) Non-nicotine pharmacotherapies for smoking cessation. Respir Med99: 1203–1212.
99.
MalinDH (2001) Nicotine dependence: Studies with a laboratory model. Pharmacol Biochem Behav70: 551–559.
100.
MalinDHGoyarzuP (2009) Rodent models of nicotine withdrawal syndrome. In: HenningfieldJELondonEDPogunS (eds) Nicotine Psychopharmacology. Berlin: Springer Berlin Heidelberg, pp.401–434.
101.
MalinDHLakeJRCarterVA, et al. (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl)115: 180–184.
102.
MalinDHLakeJRNewlin-MaultsbyP, et al. (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav43: 779–784.
103.
MalinDHLakeJRSmithTD, et al. (2006) Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl)184: 494–503.
104.
MalinDHMoonWDGoyarzuP, et al. (2013) Inhibition of monoamine oxidase isoforms modulates nicotine withdrawal syndrome in the rat. Life Sci93: 448–453.
105.
ManhãesACGuthierrezMCSFilgueirasCC, et al. (2008) Anxiety-like behavior during nicotine withdrawal predict subsequent nicotine consumption in adolescent C57BL/6 mice. Behav Brain Res193: 216–224.
106.
MannucciCTedescoMBellomoM, et al. (2006) Long-term effects of nicotine on the forced swimming test in mice: An experimental model for the study of depression caused by smoke. Neurochem Int49: 481–486.
107.
MarkouA (2008) Neurobiology of nicotine dependence. Philos Trans R Soc B Biol Sci363: 3159–3168.
108.
MarusichJADarnaMWilsonAG, et al. (2017) Tobacco’s minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats. Eur J Pharmacol814: 196–206.
109.
MattaSGBalfourDJBenowitzNL, et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl)190: 269–319.
110.
McLaughlinIDaniJADe BiasiM (2015) Nicotine withdrawal. Curr Top Behav Neurosci24: 99–123.
111.
MihalakKBCarrollFILuetjeCW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol70: 801–805.
112.
MoerkeMJMcMahonLRWilkersonJL (2020) More than smoke and patches: The quest for pharmacotherapies to treat tobacco use disorder. Pharmacol Rev72: 527–557.
113.
MontanariCKelleyLKKerrTM, et al. (2020) Nicotine e-cigarette vapor inhalation effects on nicotine & cotinine plasma levels and somatic withdrawal signs in adult male Wistar rats. Psychopharmacology (Berl)237: 613–625.
114.
MooneyMESofuogluM (2006) Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother6: 965–981.
115.
MorudJStrandbergJAndrenA, et al. (2018) Progressive modulation of accumbal neurotransmission and anxiety-like behavior following protracted nicotine withdrawal. Neuropharmacology128: 86–95.
116.
MyersWDNgKTSingerG (1982) Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. Pharmacol Biochem Behav17: 807–811.
117.
O’DellLEKhroyanTV (2009) Rodent models of nicotine reward: What do they tell us about tobacco abuse in humans?Pharmacology, biochemistry, and behavior91: 481–488.
118.
O’DellLEBruijnzeelAWSmithRT, et al. (2006) Diminished nicotine withdrawal in adolescent rats: Implications for vulnerability to addiction. Psychopharmacology (Berl)186: 612–619.
119.
O’DellLETorresOVNatividadLA, et al. (2007) Adolescent nicotine exposure produces less affective measures of withdrawal relative to adult nicotine exposure in male rats. Neurotoxicol Teratol29: 17–22.
120.
PandeySCRoyAXuT, et al. (2001) Effects of protracted nicotine exposure and withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat brain. J Neurochem77: 943–952.
121.
PangRDLeventhalAM (2013) Sex differences in negative affect and lapse behavior during acute tobacco abstinence: A laboratory study. Exp Clin Psychopharmacol21: 269–276.
PatelDRFeuchtCReidL, et al. (2010) Pharmacologic agents for smoking cessation: A clinical review. Clin Pharmacol2: 17–29.
124.
PatersonNESemenovaSMarkouA (2008) The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology (Berl)198: 351–362.
125.
PekonenKKarlssonCLaaksoI, et al. (1993) Plasma nicotine and cotinine concentrations in mice after chronic oral nicotine administration and challenge doses. Eur J Pharm Sci1: 13–18.
126.
PerezXAMcIntoshJMQuikM (2013) Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens. J Neurochem127: 762–771.
127.
PetersenDRNorrisKJThompsonJA (1984) A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos12: 725–731.
128.
PicciottoMRMineurYS (2014) Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology76(Pt B): 545–553.
129.
PietilaKAhteeL (2000) Chronic nicotine administration in the drinking water affects the striatal dopamine in mice. Pharmacol Biochem Behav66: 95–103.
130.
PietilaKLahdeTAttilaM, et al. (1998) Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol357: 176–182.
131.
PonzoniLBraidaDCarboniL, et al. (2020) Persistent cognitive and affective alterations at late withdrawal stages after long-term intermittent exposure to tobacco smoke or electronic cigarette vapour: Behavioural changes and their neurochemical correlates. Pharmacol Res158: 104941.
132.
PonzoniLMorettiMSalaM, et al. (2015) Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice. Eur Neuropsychopharmacol25: 1775–1786.
133.
PooleRLConnorDAGouldTJ (2014) Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. Behav Neurosci128: 588–593.
134.
PortugalGSGouldTJ (2007) Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol Biochem Behav88: 179–187.
135.
PortugalGSGouldTJ (2008) Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: Converging evidence from human and animal research. Behav Brain Res193: 1–16.
136.
PortugalGSWilkinsonDSKenneyJW, et al. (2012) Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet42: 133–150.
137.
ProchaskaJJBenowitzNL (2016) The past, present, and future of nicotine addiction therapy. Annu Rev Med67: 467–486.
138.
RaybuckJDGouldTJ (2009) Nicotine withdrawal-induced deficits in trace fear conditioning in C57BL/6 mice: A role for high-affinity β2 subunit-containing nicotinic acetylcholine receptors. Eur J Neurosci29: 377–387.
139.
RaybuckJDPortugalGSLermanC, et al. (2008) Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci122: 1166–1171.
140.
RehniAKSinghTGAroraS (2012) SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice. Nicotine Tob Res14: 407–414.
141.
RobinsonSFMarksMJCollinsAC (1996) Inbred mouse strains vary in oral self-selection of nicotine. Psychopharmacology (Berl)124: 332–339.
142.
RoniMARahmanS (2014) The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice. Psychopharmacology (Berl)231: 2989–2998.
143.
SchochetTLKelleyAELandryCF (2004) Differential behavioral effects of nicotine exposure in adolescent and adult rats. Psychopharmacology (Berl)175: 265–273.
144.
SemenovaSMarkouA (2010) The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur Neuropsychopharmacol20: 731–746.
145.
SemenovaSStolermanIPMarkouA (2007) Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav87: 360–368.
146.
SharmaABrodyAL (2009) In vivo brain imaging of human exposure to nicotine and tobacco. Handb Exp Pharmacol192: 145–171.
147.
ShiffmanSJohnstonJAKhayrallahM, et al. (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl)148: 33–40.
148.
ShoaibMBizarroL (2005) Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology (Berl)178: 211–222.
149.
ShramMJSiuECLiZ, et al. (2008) Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl)198: 181–190.
150.
SlemmerJEMartinBRDamajMI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther295: 321–327.
151.
SmallEShahHPDavenportJJ, et al. (2010) Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl)208: 143–158.
152.
SmithBRAmitZSplawinskyJ (1984) Conditioned place preference induced by intraventricular infusions of acetaldehyde. Alcohol1: 193–195.
153.
SparksJAPaulyJR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology (Berl)141: 145–153.
154.
StaleyJKKrishnan-SarinSCosgroveKP, et al. (2006) Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci26: 8707–8714.
155.
StokerAKSemenovaSMarkouA (2008) Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology54: 1223–1232.
156.
SuzukiTIseYMaedaJ, et al. (1999) Mecamylamine-precipitated nicotine-withdrawal aversion in Lewis and Fischer 344 inbred rat strains. Eur J Pharmacol369: 159–162.
157.
SuzukiTIseYTsudaM, et al. (1996) Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur J Pharmacol314: 281–284.
158.
TanSXueSBehnood-RodA, et al. (2019) Sex differences in the reward deficit and somatic signs associated with precipitated nicotine withdrawal in rats. Neuropharmacology160: 107756.
159.
TorresOVGentilLGNatividadLA, et al. (2013) Behavioral, biochemical, and molecular indices of stress are enhanced in female versus male rats experiencing nicotine withdrawal. Front Psychiatry4: 38.
160.
TorresOVPipkinJAFerreeP, et al. (2015) Nicotine withdrawal increases stress-associated genes in the nucleus accumbens of female rats in a hormone-dependent manner. Nicotine Tob Res17: 422–430.
161.
UlusuUUzbayITKayirH, et al. (2005) Evidence for the role of nitric oxide in nicotine-induced locomotor sensitization in mice. Psychopharmacology (Berl)178: 500–504.
162.
van der StaayFJArndtSSNordquistRE (2009) Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct5: 11.
163.
VaraniAPPedronVTMachadoLM, et al. (2015) Lack of GABAB receptors modifies behavioural and biochemical alterations induced by precipitated nicotine withdrawal. Neuropharmacology90: 90–101.
164.
VoikarVPolusAVasarE, et al. (2005) Long-term individual housing in C57BL/6J and DBA/2 mice: Assessment of behavioral consequences. Genes Brain Behav4: 240–252.
165.
WatkinsSSStinusLKoobGF, et al. (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther292: 1053–1064.
166.
WileyJLMarusichJAThomasBF, et al. (2015) Determination of behaviorally effective tobacco constituent doses in rats. Nicotine Tob Res17: 368–371.
167.
WilkingJAHesterbergKGNguyenVH, et al. (2012) Comparison of nicotine oral consumption and baseline anxiety measures in adolescent and adult C57BL/6J and C3H/Ibg mice. Behav Brain Res233: 280–287.
168.
WilkinsonDSGouldTJ (2011) The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res223: 53–57.
169.
WillnerPMitchellPJ (2002) The validity of animal models of predisposition to depression. Behav Pharmacol13: 169–188.
170.
WingVCShoaibM (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl)195: 303–313.
171.
XiZXSpillerKGardnerEL (2009) Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin30: 723–739.
172.
XueSBehnood-RodAWilsonR, et al. (2018) Rewarding effects of nicotine in adolescent and adult male and female rats as measured using intracranial self-stimulation. Nicotine Tob Res. Epub ahead of print 20 November 2018. DOI: 10.1093/ntr/nty249.
173.
ZaniewskaMMcCrearyACWydraK, et al. (2010) Effects of serotonin (5-HT) 2 receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology58: 1140–1146.
174.
Zhao-SheaRDeGrootSRLiuL, et al. (2015) Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Nat Commun6: 6770.
175.
Zhao-SheaRLiuLPangX, et al. (2013) Activation of GABAergic neurons in the interpeduncular nucleus triggers physical nicotine withdrawal symptoms. Curr Biol23: 2327–2335.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
